Investment Rating - The report maintains a "Recommended" rating for the pharmaceutical industry [5] Core Insights - The underlying logic of the current pharmaceutical industry era is innovation and international expansion, with a focus on innovative drugs and technology-driven sectors [2][3] - The report highlights the strong performance of the CRO market and suggests a dual investment strategy focusing on both "0 to 1" technology innovation and low-position stocks [2][3] - The report emphasizes the ongoing trend of BD (Business Development) transactions in innovative drugs, with significant growth expected in 2026 [4][15] Summary by Sections 1. Key Events in the Pharmaceutical Industry During the Spring Festival - Innovative drug BD transactions have seen a strong start, with significant overseas development and registration progress for key products [13][14] - The total amount of BD transactions for innovative drugs in China for 2026 has already surpassed one-third of the total for 2025 [15] - The revision of the National Essential Medicines List Management Measures may signal changes in the essential medicines directory [28] 2. Pharmaceutical Market Review and Hotspot Tracking - The pharmaceutical sector's performance was relatively weak, with a weekly decline of 0.81%, ranking 20th among all industries [34][38] - The total trading volume for pharmaceuticals was 401.12 billion yuan, accounting for 3.83% of the total market, below the historical average of 7.09% [55] - The report notes a rising valuation level for the pharmaceutical industry, with a PE ratio of 29.25, which is below the historical average [52] 3. Stock Performance Review - The report lists the top-performing stocks, including Dongyangguang and Zhendemedical, while highlighting the underperformers like Huayuan Biology and *ST Sailong [58][59]

中国经济网北京2月21日讯 泽璟制药（688266.SH）2月14日披露《股东及董事、高级管理人员减持 股份计划公告》。 根据公告，控股股东、实际控制人之一、董事长、总经理ZELIN SHENG（盛泽林）因自身资金需 求，拟通过集中竞价或大宗交易方式减持公司股份数量不超过273,907股，即不超过公司总股本的 0.1035%；股东宁波泽奥创业投资合伙企业（有限合伙）（以下简称"宁波泽奥"）拟通过集中竞价或大 宗交易方式减持公司股份数量不超过2,475,090股，即不超过公司总股本的0.9350%。上述减持计划的减 持期间为自公告披露之日15个交易日后3个月内，减持价格将根据减持时的市场价格确定。 按2月13日公司收盘价94.42元计算，ZELIN SHENG（盛泽林）拟减持套现合计约25,862,298.94元， 宁波泽奥拟减持套现合计约233,697,997.80元，两者合计拟减持套现约259,560,296.74元。 截至公告披露日，ZELIN SHENG（盛泽林）直接持有公司股份49,910,527股，占公司总股本的 18.8549%，股份来源于公司首次公开发行前持有及二级市场增持；ZELIN SHEN ...

Core Viewpoint - Zai Lab (688266) has entered a strategic collaboration with AbbVie for the global development and commercialization of ZG006, receiving an upfront payment of $100 million and potential milestone payments up to $1.075 billion, along with tiered royalties [1][4]. Group 1: Company Developments - Zai Lab's stock price increased by 3.27% this week, closing at 94.42 CNY, with a market capitalization of 24.994 billion CNY, ranking 16th in the chemical pharmaceutical sector [1]. - ZG006 has shown significant efficacy in treating small cell lung cancer, with an overall response rate (ORR) of 60.0% in the recommended dose group and a confirmed ORR of 53.3% [1][4]. - ZG005 has demonstrated an ORR of 40.9% in second-line and above cervical cancer patients, with a median progression-free survival (mPFS) exceeding 11 months [2][4]. - The injection of human thyroid-stimulating hormone beta (Zesuneng) was approved on January 8 for use in post-operative follow-up of differentiated thyroid cancer, with marketing efforts led by Merck in China [2][4]. - The drug Jikaxitini tablets were included in the national medical insurance directory effective January 1, 2026, and are recommended as a first-line treatment for anemia in myelofibrosis [2][4]. Group 2: Financial Performance - The company expects its revenue for 2025 to be between 796.49 million CNY and 828.99 million CNY, representing a year-on-year growth of 49.45% to 55.55%, primarily driven by increased sales of recombinant thrombin and the launch of Jikaxitini tablets [3][4]. - Despite revenue growth, the company anticipates a net loss due to increased sales and research expenses [3]. Group 3: Shareholder Actions - The chairman and major shareholder, Zelin Sheng, plans to reduce his holdings by up to 273,907 shares (0.1035%), while Ningbo Zeao intends to reduce its holdings by up to 2,475,090 shares (0.9350%) between March 17 and June 16, 2026 [3][4].

Core Viewpoint - The article discusses the current funding logic in the market, highlighting the significant movements of public funds in the technology sector, particularly in the semiconductor and biopharmaceutical industries, as they adjust their portfolios based on performance and valuation metrics [3][8]. Group 1: Public Fund Movements - Public funds have shown a notable shift in their holdings, particularly in the STAR Market, with the STAR 50 Index rising by 12.1% this year [3][4]. - The total market capitalization of STAR Market companies reached 10.4 trillion yuan, with the technology sector dominating, accounting for 62.1% of the total market cap [5][6]. - The semiconductor industry remains the core focus for fund allocation, with 12 companies in the sector having a market capitalization exceeding 10 billion yuan [9][11]. Group 2: Semiconductor Sector Insights - The market's pricing anchor for the semiconductor sector has shifted from "valuation expansion" to "performance realization," emphasizing the importance of actual earnings [13][14]. - Key drivers for future growth in the semiconductor sector include strong order backlogs, profit growth through acquisitions and expansions, and sustained price increases in advanced processes [13][14]. - Public funds have significantly increased their holdings in semiconductor materials, chip design, and equipment, with companies like ShenGong Co. seeing an 11% increase in fund holdings [15][21]. Group 3: Biopharmaceutical Sector Insights - The biopharmaceutical sector is a critical area for public funds, with major holdings in companies like BeiGene and United Imaging Healthcare, although the sector has faced a reduction in holdings for several key companies [24][26]. - The article notes that innovative drug companies are currently under pressure, with significant reductions in holdings observed in companies like BaiLi TianHeng and RongChang Biopharma [26][28]. - Despite the challenges, companies with strong earnings potential and innovative drug pipelines are still attracting interest from public funds, indicating a selective investment approach [35][40].

业绩经营情况 公司预计2026年营收为7.96亿至8.29亿元，同比增长49.45%至55.55%，主要受益于重组人凝血酶医保放 量及吉卡西替尼商业化推进。 泽璟制药与艾伯维就ZG006药物达成全球开发及商业化协议，艾伯维获得大中华区以外独家权利；泽璟 已收到1亿美元首付款，并可能获得最高6000万美元近期里程碑付款及10.75亿美元远期里程碑付款。 ZG006针对小细胞肺癌和神经内分泌癌的临床试验数据显示，在II期剂量优化试验中，10mg组确认客观 缓解率（ORR）达53.3%，中位无进展生存期（mPFS）为7.03个月。 产品研发进展 除ZG006外，注射用ZG005在宫颈癌II期临床试验中确认ORR为40.9%，疾病控制率（DCR）68.2%；公 司多款候选药物如ZGGS18、ZGGS34等已进入中美I期临床阶段。 经济观察网 根据截至2026年2月14日的公开信息，泽璟制药-U（688266.SH）近期有以下事件值得关 注： 高管减持 公司公告称，股东ZELIN SHENG（盛泽林）拟减持不超过273,907股（占总股本0.1035%），股东宁波 泽奥拟减持不超过2,475,090股（占总股本0.93 ...

Core Viewpoint - On February 13, there were no announcements of share buybacks, but several companies announced share reductions, indicating a trend of selling among major stakeholders [1][3]. Group 1: Companies Announcing Share Reductions - Zhaolong Interconnect: Directors Song Hongxia and Deputy General Manager Shen Fuliang plan to reduce their holdings by 0.0110% [2][4]. - Gaoc测股份: The controlling shareholder and three directors plan to collectively reduce their holdings by up to 3.19% [2][4]. - ST Yigou: Shareholder Hangzhou Haoyue intends to reduce holdings by no more than 2.5% [2][4]. - Xiandao Jidian: Shareholder Sanlin Wanye plans to reduce holdings by up to 2.05% [2][4]. - Guanghuan Xinwang: The controlling shareholder Baihuida intends to reduce holdings by up to 3% [2][4]. - Chunqiu Electronics: The controlling shareholder Xue Gewen plans to reduce holdings by up to 2% [2][4]. - New Coordinates: Shareholders plan to collectively reduce holdings by up to 0.0795% [2][4]. - Zejing Pharmaceutical: Shareholders plan to collectively reduce holdings by up to 1.0385% [2][4].

泽璟制药2月13日公告，公司控股股东、实际控制人之一、董事长、总经理盛泽林及股东宁波泽奥创业 投资合伙企业（有限合伙）因自身资金需求，计划自公告披露之日起15个交易日后的3个月内，通过集 中竞价或大宗交易方式减持公司股份。其中，盛泽林拟减持不超过27.39万股，即不超过公司总股本的 0.1035%；宁波泽奥拟减持不超过247.51万股，即不超过公司总股本的0.9350%。减持价格将根据减持时 的市场价格确定。本次减持计划实施具有不确定性。 ...

Core Viewpoint - The news summarizes important announcements from various companies, highlighting significant developments in their operations and financial performance. Company Announcements - Tianfeng Securities received a notice from the China Securities Regulatory Commission regarding a case of information disclosure violation related to Fujian Yong'an Forestry Group, and the company will cooperate with the investigation [3] - Southwest Securities plans to raise no more than 6 billion yuan through a private placement to supplement its capital and optimize its capital structure [4] - Qiaoyin Co. has terminated its investment in the artificial intelligence industry headquarters project due to changes in cooperation conditions, with a planned investment of no more than 1 billion yuan [5] - Zongshen Power is planning a major asset swap with Longxin General, aiming to resolve competition issues and promote clearer business development [6] - Laimei Pharmaceutical's selected products for national centralized procurement are expected to generate 106 million yuan in sales for 2024, accounting for 13.35% of the company's revenue [7] Performance Reports - Huayin Technology reported a net profit of 313 million yuan for 2025, a decrease of 24.28%, with revenue of 1.251 billion yuan, up 9.83% [9] - Youlide announced a net profit of 152 million yuan for 2025, down 16.88%, with revenue of 1.221 billion yuan, up 7.99% [10][11] - Fudan Microelectronics reported a net profit of 232 million yuan for 2025, a decline of 59.42%, with revenue of 3.982 billion yuan, up 10.92% [12] - Hanzhong Precision reported a net profit of 470 million yuan for 2025, down 45.54%, with revenue of 2.928 billion yuan, a decrease of 20.32% [13] Shareholding Changes - Gaomei Co.'s controlling shareholder and several directors plan to reduce their holdings by up to 3.19% of the company's shares [15] - Guanghuan New Network's controlling shareholder intends to reduce its stake by up to 3% [16] - ST Yigou's shareholder plans to reduce its holdings by up to 2.5% [17] - Juguang Technology's shareholders plan to collectively reduce their holdings by up to 2.3339% [18] - Xiandai Jidian's shareholder intends to reduce its stake by up to 2.05% [19] - Zhejing Pharmaceutical's shareholders plan to reduce their holdings by up to 1.0385% [21] Contract Signings - China Nuclear Construction signed contracts worth 3.393 billion yuan in January, with total revenue of 7.69 billion yuan [23] - China Chemical signed contracts totaling 36.925 billion yuan in January, including significant contracts over 500 million yuan [24]

2026年2月13日，泽璟制药披露接待调研公告，公司于2月2日至2月10日接待淡水泉、农银汇理、安信基 金、华安基金、建信资产、平安基金等28家机构调研。 调研情况显示，泽璟制药与艾伯维就ZG006达成全球开发及商业化战略合作与许可选择权协议，艾伯维 获大中华区以外地区独家权利，泽璟保留区内权利；泽璟已收到1亿美元首付款，还可获最高6000万美 元近期里程碑及许可选择付款，若选择权行使另有最高10．75亿美元里程碑付款和高个位数到中双位数 阶梯特许权使用费。ZG006正推进单药及联合用药治疗小细胞肺癌、神经内分泌癌等临床试验，包括关 键及III期试验；在晚期小细胞肺癌三线及以上II期剂量优化试验中，10mg每两周一次组确认ORR为53． 3％、mPFS达7．03个月，6个月及12个月OS率分别为83．2％及69．1％；治疗神经内分泌癌推荐剂量 组全人群确认ORR38．5％，DLL3阳性患者达66．7％。 注射用ZG005正推进单药及联合用药治疗肝癌、神经内分泌癌、宫颈癌等试验；二线及以上宫颈癌 20mg／kg Q3W方案确认ORR40．9％、DCR68．2％、mPFS超11个月，联合方案一线宫颈癌及早期肝 癌 ...

证券代码：688266 证券简称：泽璟制药 公告编号：2026-007 苏州泽璟生物制药股份有限公司 股东及董事、高级管理人员减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 股东及董事、高级管理人员持股的基本情况 截至本公告披露日，苏州泽璟生物制药股份有限公司（以下简称"公司"）控 股股东、实际控制人之一、董事长、总经理 ZELIN SHENG（盛泽林）先生直接 持有公司股份 49,910,527 股，占公司总股本的 18.8549%，股份来源于公司首次 公开发行前持有及二级市场增持；ZELIN SHENG（盛泽林）先生一致行动人、 实际控制人之一、董事、常务副总经理陆惠萍女士直接持有公司股份 12,631,644 股，占公司总股本的 4.7719%，股份来源于公司首次公开发行前持有、股权激励 计划归属及二级市场增持；上述一致行动人合计持有公司股份 62,542,171 股，占 公司总股本的 23.6268%。股东宁波泽奥创业投资合伙企业（有限合伙）（以下简 称"宁波泽奥"）直 ...